西地那非
医学
药理学
勃起功能障碍
一氧化氮
环磷酸鸟苷
cGMP特异性磷酸二酯酶5型
药品
心肌梗塞
细胞凋亡
活性氧
坏死性下垂
重新调整用途
磷酸二酯酶
心脏病学
纳米医学
磷酸二酯酶抑制剂
内科学
声动力疗法
联合疗法
药物重新定位
体内分布
细胞保护
治疗效果
病态的
作者
Fang Zhang,Haoyi Yuan,Xueping Zeng,Keqiang Lu,Yunyun Zhou,Juanjuan Peng,Lingzhi Zhao
标识
DOI:10.1021/acsanm.6c03277
摘要
Abstract Reperfusion therapy is the standard treatment for acute myocardial infarction, yet it paradoxically induces myocardial ischemia−reperfusion injury (MI/RI), resulting in further cardiomyocyte loss. Effective therapies for MI/RI therefore remain a major unmet clinical need. Sildenafil, a clinically approved phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction and pulmonary arterial hypertension, has shown potential cardioprotective activity through the enhancement of nitric oxide−cyclic guanosine monophosphate (NO−cGMP) signaling and vasodilation. However, its therapeutic utility in MI/RI is limited by nonspecific biodistribution and insufficient accumulation at the site of injury. Here, we developed a reactive oxygen species-responsive, silica-cross-linked micellar nanoplatform for systemic sildenafil delivery. This nanoplatform promotes preferential accumulation in the infarcted myocardium and enables ROS-triggered drug release within the pathological microenvironment. In a rat model of MI/RI, intravenous administration of the nanomedicine significantly improved cardiac function, reduced apoptosis and fibrosis, and markedly alleviated myocardial injury. These findings highlight a promising therapeutic strategy for MI/RI and support the expanded clinical application of sildenafil.
科研通智能强力驱动
Strongly Powered by AbleSci AI